Table 1. Characteristics of the study population.
| N (%) | |
|---|---|
| Total | 464 |
| Age (mean – SD) | 65.8 (11.5) |
| Race | |
| Caucasian | 207 (44.6%) |
| Non-Caucasian | 257 (55.4%) |
| PS | |
| 0 | 116 (25.4%) |
| 1 | 295 (64.7%) |
| 2 | 33 (7.2%) |
| 3 | 12 (2.6%) |
| Type of surgery | |
| TAH | 14 (3.0%) |
| TAH + BSO | 131 (28.3%) |
| TAH + BSO + LN | 156 (33.7%) |
| TAH + BSO + LN + Omentectomy | 162 (35.0%) |
| Histology | |
| ECG3 | 145 (31.2%) |
| Serous | 118 (25.4%) |
| Clear cell | 44 (9.5%) |
| Carcinosarcoma | 63 (13.6%) |
| Mixed | 91 (19.6%) |
| SOE | 3 (0.6%) |
| FIGO stage | |
| I | 207 (44.6%) |
| II | 58 (12.5%) |
| III | 139 (30.0%) |
| IV | 60 (12.9%) |
| Myometrial invasion | |
| <50% | 236 (51.0%) |
| >50% | 227 (49.0%) |
| p53 status | |
| Wild type | 113 (25.7%) |
| Aberrant | 327 (74.3%) |
| L1CAM status | |
| Negative | 205 (46.5%) |
| Positive | 236 (53.5%) |
| p53/L1CAM | |
| p53wt/L1CAMneg | 59 (13.6%) |
| p53wt/L1CAMpos | 51 (11.7%) |
| p53ab/L1CAMneg | 143 (32.9%) |
| p53ab/L1CAMpos | 182 (41.8%) |
| Treatment | |
| Observation | 103 (22.2%) |
| CT with/without RT | 235 (50.8%) |
| RT and/or BT | 125 (27.0%) |
| Relapse | |
| No | 259 (55.9%) |
| Yes | 204 (44.1%) |
| Death | |
| No | 198 (42.7%) |
| Yes | 266 (57.3%) |
Abbreviations: SD, standard deviation; TAH, total abdominal hysterectomy; BSO, bilateral salpingoophorectomy; LN, lymphadenectomy; ECG3, endometrioid carcinoma grade 3; CT, adjuvant chemotherapy; RT, adjuvant radiotherapy; BT, adjuvant brachytherapy